Andrew Booth insider trades: AbCellera Biologics (ABCL) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Andrew reports to the SEC
Open-market buys and sales
7 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026 | ABCL | ↑ Buy | 37,200 | $10.32 | $384K | Direct | Aug 14, 2026 (0d) |
| Feb 27, 2026 | ABCL | ↑ Buy | 42,600 | $3.42 | $146K | Direct | Feb 27, 2026 (0d) |
| May 26, 2023 | ABCL | ↑ Buy | 14,500 | $6.85 | $99K | Direct | May 26, 2023 (0d) |
| May 12, 2022 | ABCL | ↑ Buy | 85,000 | $5.79 | $492K | Direct | May 16, 2022 (4d) |
| Nov 11, 2021 | ABCL | ↑ Buy | 53,500 | $14.74 | $789K | Direct | Nov 15, 2021 (4d) |
| Nov 11, 2021 | ABCL | ↑ Buy | 14,000 | $14.61 | $205K | By spouse | Nov 15, 2021 (4d) |
| Jun 9, 2021 | ABCL | ↓ Sell | 1,200,000 | $25.50 | $30.6M | Direct | Jun 10, 2021 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ABCL insiders
Open-market trades in the last 12 months
About Andrew Booth's insider trades
Andrew Booth is Chief Financial Officer at AbCellera Biologics (ABCL). Since Jun 9, 2021, Andrew has reported 6 open-market purchases worth $2.1M and 1 sale worth $30.6M on SEC Form 4. In the last 12 months: 2 buys ($530K).
Their filings also include grants and awards (5 filings), option exercises (4 filings), gifts (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ABCL insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.